CanaQuest Medical Corp

CanaQuest, a clinical-stage life sciences company, develops innovative cannabinoid-based therapeutics. Our focus, CQ-001, combines cannabidiol (CBD) with Omega-3 fatty acids to treat refractory epilepsy in 30%-40% of the 65 million affected people worldwide. This drug enhances binding to receptors in the brain, showing a 35% increase in potency over isolated CBD in pre-clinical models. Our expertise with FDA-approved cannabidiol (Epidiolex®) positions us at the forefront of epilepsy treatment.